Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Trazodone
Drug ID BADD_D02266
Description Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants.[A181180] It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of depression.[T646] A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and SNRI therapy.[T646] Trazodone acts on various receptors, including certain histamine, serotonin, and adrenergic receptors, distinguishing it from other antidepressants that cover a narrow range of neurotransmitters.[T646] It was initially granted FDA approval in 1981.[L3484]
Indications and Usage Trazodone is indicated for the treatment of major depressive disorder (MDD).[L3484] It has been used off-label for adjunct therapy in alcohol dependence, and off-label to treat anxiety and insomnia.[L3484] It may also be used off-label to treat symptoms of dementia, Alzheimer’s disease, schizophrenia, eating disorders, and fibromyalgia due to its effects on various neurotransmitter receptors.[A31634]
Marketing Status approved; investigational
ATC Code N06AX05
DrugBank ID DB00656
KEGG ID D08626
MeSH ID D014196
PubChem ID 5533
TTD Drug ID D00USF
NDC Product Code Not Available
UNII YBK48BXK30
Synonyms Trazodone | Tradozone | AF-1161 | AF 1161 | AF1161 | Deprax | Desyrel | Gen-Trazodone | Gen Trazodone | Molipaxin | Novo-Trazodone | Novo Trazodone | Trittico | PMS-Trazodone | PMS Trazodone | Ratio-Trazodone | Ratio Trazodone | RatioTrazodone | Thombran | Trazodon Hexal | Trazodon-Neuraxpharm | Trazodon Neuraxpharm | TrazodonNeuraxpharm | Trazodone Hydrochloride | Trazon | Apo-Trazodone | Apo Trazodone | Nu-Trazodone | Nu Trazodone
Chemical Information
Molecular Formula C19H22ClN5O
CAS Registry Number 19794-93-5
SMILES C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Leukocytosis01.02.01.002--
Libido decreased19.08.03.001; 21.03.02.005--
Libido increased21.03.02.007; 19.08.03.002--
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.003--
Mean arterial pressure13.14.03.018--Not Available
Memory impairment19.20.01.003; 17.03.02.003--
Menstruation irregular21.01.01.005; 05.05.01.008--
Mental disability26.01.01.001--Not Available
Mental impairment19.21.02.003; 17.03.03.002--Not Available
Methaemoglobinaemia01.05.01.002--
Micturition urgency20.02.02.006--
Middle insomnia17.15.03.003; 19.02.01.0030.000065%Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Miosis17.02.11.002; 06.05.03.003--Not Available
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.005--Not Available
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nail discolouration23.02.05.001--
Nasal congestion22.04.04.001--
Nausea07.01.07.0010.000107%
Neoplasm16.16.02.001--Not Available
Nervousness19.06.02.003--Not Available
Neuroleptic malignant syndrome17.05.02.003; 15.05.04.015; 12.03.01.003; 08.05.01.005--Not Available
Night sweats23.02.03.006; 08.01.03.031--Not Available
Nightmare19.02.03.003--Not Available
Ocular hyperaemia06.04.05.004--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
The 5th Page    First    Pre   5 6 7 8    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene